公开(公告)号：US20240228464A9

公开(公告)日：2024-07-11

申请号：US18383949

申请日：2023-10-26

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Brett Granger ,  Jing He ,  Xuechao Xing ,  Yong He ,  Jiang Long ,  Jun Ma ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:




which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

公开(公告)号：US20240207224A1

公开(公告)日：2024-06-27

申请号：US18509403

申请日：2023-11-15

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Jiajun Zhang ,  Xuri Gao ,  Hui Cao ,  Yuk Ming Siu ,  Bin Wang ,  Jiang Long ,  Wei Li ,  Matthew C. Rhodes ,  Xuechao Xing ,  Scott Mitchell ,  Yat Sun Or

IPC: A61K31/395 ,  A61K31/4192 ,  A61K31/4995 ,  A61P31/14 ,  C07D225/04 ,  C07D245/04 ,  C07D255/04 ,  C07D273/02 ,  C07D281/00 ,  C07D285/00 ,  C07D487/08

CPC classification number: A61K31/395 ,  A61K31/4192 ,  A61K31/4995 ,  A61P31/14 ,  C07D225/04 ,  C07D245/04 ,  C07D255/04 ,  C07D273/02 ,  C07D281/00 ,  C07D285/00 ,  C07D487/08

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11034684B2

公开(公告)日：2021-06-15

申请号：US16569819

申请日：2019-09-13

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jun Ma ,  Guoqiang Wang ,  Bin Wang ,  Xuechao Xing ,  Ruichao Shen ,  Jing He ,  Yat Sun Or

IPC: C07D417/14 ,  C07D413/14 ,  C07D261/08 ,  C07D413/12

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

公开(公告)号：US11008304B2

公开(公告)日：2021-05-18

申请号：US16400529

申请日：2019-05-01

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Brett Granger ,  Jing He ,  Xuechao Xing ,  Yong He ,  Jiang Long ,  Jun Ma ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D413/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

公开(公告)号：US20200157095A1

公开(公告)日：2020-05-21

申请号：US16688429

申请日：2019-11-19

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Brett Granger ,  Guoqiang Wang ,  Ruichao Shen ,  Jing He ,  Yong He ,  Xuechao Xing ,  Jun Ma ,  Jiang Long ,  Bin Wang ,  Yat Sun Or

IPC: C07D471/04 ,  C07D401/14 ,  C07D413/14 ,  C07D405/14 ,  C07D417/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US20200079764A1

公开(公告)日：2020-03-12

申请号：US16569819

申请日：2019-09-13

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jun Ma ,  Guoqiang Wang ,  Bin Wang ,  Xuechao Xing ,  Ruichao Shen ,  Jing He ,  Yat Sun Or

IPC: C07D413/14 ,  C07D413/12 ,  C07D261/08 ,  C07D417/14

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

公开(公告)号：US10584145B2

公开(公告)日：2020-03-10

申请号：US15826233

申请日：2017-11-29

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Yong He ,  Peng Dai ,  Guoyou Xu ,  Bin Wang ,  Jiang Long ,  Yat Sun Or

IPC: C07J41/00 ,  C07J51/00 ,  C07J9/00

Abstract: The present invention relates to processes for preparing a compound of Formula I: or a pharmaceutically acceptable salt or solvate thereof. These compounds and pharmaceutical compositions are useful as FXR or TGR5 modulators. Specifically, the present invention relates to bile acid derivatives and methods for their preparation and use. The present invention relates to a process for the preparation of a compound (II) and its salts and derivatives which are useful intermediates in the synthesis of biologically active molecules, especially in the synthesis of FXR and TGR5 modulators. The present invention also relates to a process for the preparation of a compound (III) and its diethylamine salt.

公开(公告)号：US10253018B2

公开(公告)日：2019-04-09

申请号：US15988763

申请日：2018-05-24

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Brett Granger ,  Ruichao Shen ,  Yong He ,  Xuechao Xing ,  Jun Ma ,  Jiang Long ,  Jing He ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D401/04 ,  C07D491/107 ,  C07D498/08

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US10144729B2

公开(公告)日：2018-12-04

申请号：US15597417

申请日：2017-05-17

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Jun Ma ,  Bin Wang ,  Yong He ,  Xuechao Xing ,  Ruichao Shen ,  Brett Granger ,  Jing He ,  Jiang Long ,  Guoqiang Wang

IPC: A61K31/42 ,  C07D413/12 ,  C07D261/08

Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.

公开(公告)号：US10080742B2

公开(公告)日：2018-09-25

申请号：US15497307

申请日：2017-04-26

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Ruichao Shen ,  Xuechao Xing ,  Brett Granger ,  Bin Wang ,  Jun Ma ,  Jing He ,  Yong He ,  Jiang Long ,  Guoqiang Wang

IPC: C07D417/14 ,  C07D413/12 ,  C07D413/14 ,  A61K31/42 ,  A61K31/426 ,  A61K31/4725 ,  A61K31/545 ,  A61K31/64 ,  C07D261/08 ,  C07D275/04 ,  C07D277/62

CPC classification number: A61K31/42 ,  A61K31/426 ,  A61K31/4725 ,  A61K31/545 ,  A61K31/64 ,  C07D261/08 ,  C07D275/04 ,  C07D277/62 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.